Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic
- PMID: 14715557
- PMCID: PMC321355
- DOI: 10.1128/cdli.11.1.119-122.2004
Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic
Abstract
Despite almost universal use of measles vaccines in recent decades, epidemics of the disease continue to occur. Understanding the role of primary vaccine failure (failure to seroconvert after vaccination) and secondary vaccine failures (waning immunity after seroconversion) in measles epidemics is important for the evaluation of measles control programs in developing countries. After a measles epidemic in São Paulo, Brazil, 159 cases previously confirmed by detection of specific immunoglobulin M (IgM) antibodies were tested for IgG avidity, and a secondary immune response, defined by an IgG avidity index of at least 30%, was established in 30 of 159 (18.9%) patients. Among the 159 patients, 107 (67.3%) had not been vaccinated and 52 (32.7%) had received one or more doses of measles vaccine. Of the 107 unvaccinated patients, 104 (97.2%) showed a primary immune response, defined as an IgG avidity index of less than 30%. Among the 52 patients with documented vaccination, 25 (48.1%) showed a primary immune response and 27 (51.9%) showed a secondary immune response, thereby constituting a secondary vaccine failure. Primary vaccine failure was observed in 13 of 13 patients vaccinated prior to 1 year of age and in 43.5 and 12.5%, respectively, of patients receiving one or two doses after their first birthdays. These results provide evidence that measurement of IgG avidity can be used to distinguish between primary and secondary vaccine failures in vaccinated patients with measles; the method can also be a useful tool for the evaluation of measles control programs.
Similar articles
-
Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.Epidemiol Infect. 2000 Apr;124(2):263-71. doi: 10.1017/s0950268899003222. Epidemiol Infect. 2000. PMID: 10813152 Free PMC article.
-
Distinguishing between primary measles infection and vaccine failure reinfection by IgG avidity assay.East Mediterr Health J. 2006 Nov;12(6):775-82. East Mediterr Health J. 2006. PMID: 17333822
-
Measles Virus IgG Avidity Assay for Use in Identification of Measles Vaccine Failures in Tianjin, China.Biomed Environ Sci. 2019 Nov;32(11):804-811. doi: 10.3967/bes2019.102. Biomed Environ Sci. 2019. PMID: 31910938
-
The resurgence of measles in the United States, 1989-1990.Annu Rev Med. 1992;43:451-63. doi: 10.1146/annurev.me.43.020192.002315. Annu Rev Med. 1992. PMID: 1580601 Review.
-
IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy.Expert Opin Pharmacother. 2003 Aug;4(8):1215-25. doi: 10.1517/14656566.4.8.1215. Expert Opin Pharmacother. 2003. PMID: 12877632 Review.
Cited by
-
Characterization of Vaccine Breakthrough Cases during Measles Outbreaks in Milan and Surrounding Areas, Italy, 2017-2021.Viruses. 2022 May 17;14(5):1068. doi: 10.3390/v14051068. Viruses. 2022. PMID: 35632809 Free PMC article.
-
Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019.Vaccines (Basel). 2021 Mar 13;9(3):256. doi: 10.3390/vaccines9030256. Vaccines (Basel). 2021. PMID: 33805681 Free PMC article.
-
The Chlamydia M278 Major Outer Membrane Peptide Encapsulated in the Poly(lactic acid)-Poly(ethylene glycol) Nanoparticulate Self-Adjuvanting Delivery System Protects Mice Against a Chlamydia muridarum Genital Tract Challenge by Stimulating Robust Systemic and Local Mucosal Immune Responses.Front Immunol. 2018 Oct 15;9:2369. doi: 10.3389/fimmu.2018.02369. eCollection 2018. Front Immunol. 2018. PMID: 30374357 Free PMC article.
-
The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.Expert Rev Vaccines. 2013 Jan;12(1):57-70. doi: 10.1586/erv.12.134. Expert Rev Vaccines. 2013. PMID: 23256739 Free PMC article. Review.
-
FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial.J Med Virol. 2017 Jul;89(7):1255-1264. doi: 10.1002/jmv.24750. Epub 2016 Dec 26. J Med Virol. 2017. PMID: 27943311 Free PMC article. Clinical Trial.
References
-
- Camargo, M. C., J. C. Moraes, V. A. Souza, M. R. Matos, and C. S. Pannuti. 2000. Predictors related to the occurrence of a measles epidemic in the city of Sao Paulo in 1997. Pan. Am. J. Public Health 7:359-365. - PubMed
-
- Centers for Disease Control and Prevention. 1991. Measles. United States, 1990. Morb. Mortal. Wkly. Rep. 40:369-372. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical